METROSIL
2.3.2016 04:01:55 CET | Business Wire | Press release
Metrosil , the world leader in silicon carbide non-linear resistors (called varistors) today announced the launch of its new range of De-Excitation Units - the “Metrosil 8000 Series”, designed to protect large electrical generators. The all-new 8000 Series (protected by Registered Design) has been developed around an improved ergonomic structure, an industry first, providing not only protection for the varistor discs, but also simplifying the installation of the units. Another unique feature is the inclusion of a high energy test certificate with every 8000 Series unit, providing proof that the varistors perform as required. De-Excitation varistors protect electricity generating equipment (for example in hydropower and nuclear installations) from the damaging effects of powerful high energy surges.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160301006459/en/
8000 Series features include:
- Protective bar to prevent accidental disc damage
- Anti-tamper device to ensure unit integrity
- Ergonomic handles for easy carrying and installation
- Robust, easy-access connection points
- Range of standard footprints enables consistent installation
- Nameplate –permanently displays the unit’s specification details
- Each unit shipped with certification of high energy testing
- Clearly labelled with High Energy Test “Pass” badge
James O’Brien, Metrosil’s Product Group Director, commented “Metrosil constantly innovates and responds to customer feedback. With its new design, anti-tamper and ergonomic features, the 8000 Series is a more robust, long-lasting product. All Metrosil excitation products are tested to 100% of its specification – it’s part of what makes us unique in the industry, and we’re thrilled to launch another Metrosil first for the power generation industry.”
The Metrosil commercial team will be showing the 8000 Series at industry trade shows and also to individual utilities and power generation companies. To arrange a Metrosil 8000 Series visit, email requests should be sent to Ian Rowley, Metrosil’s Business Development Manager: ianrowley@mimaterials.com .
Ends
About Metrosil
Metrosil is the leading brand of high performance over-voltage protection devices for a wide range of power generation and transmission applications around the globe. It is a product of M&I Materials Limited in Manchester, UK. Since 1936, millions of Metrosil varistors have been sold throughout the world, used in flagship power projects including:
- Three Gorges Hydroelectric Dam, China
- La Grande, Canada
- Grand Coulee Dam, USA
- Itaipu, Brazil/Paraguay
About M&I Materials Limited
M&I Materials Limited is an international manufacturing company producing Specialist Materials for Industry and Science to customers located in more than sixty countries worldwide. www.mimaterials.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160301006459/en/
Contact:
M&I Materials Ltd
Ian Rowley, Metrosil Business Development
Manager
Tel: +44 (0) 161 864 5490
E-mail: ianrowley@mimaterials.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
Seiden Law LLP States: Cambodian Businessman Leak Yim, Wrongfully Accused in Thailand, Seeks Redress in U.S. Court29.6.2026 06:00:00 CEST | Press release
Seiden Law LLP (“Seiden Law”), legal counsel for Mr. Leak Yim, a Cambodia national, and his family, announces the filing of an application in U.S. federal district court in Washington D.C., seeking court-ordered discovery to uncover the false and misleading information that may have led to mistaken prosecution in Thailand of Mr. Yim as well as his unwarranted identification to Congress as being associated with scam centers in Asia. 28 U.S.C. § 1782 (“1782”) provides powerful evidence-gathering remedies, permitting an applicant to obtain evidence in the United States to assist international proceedings. Seiden Law, a U.S. law firm with significant experience in 1782 cases, has filed this application to compel production of documents and sworn testimony from persons in the U.S. that will shed light on the circumstances surrounding recent actions against Mr. Yim. “Mr. Yim and his young family are the apparent victims of guilt by association and political persecution,” said Robert Seiden,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom